Status | Study |
Not yet recruiting |
Study Name: Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL Condition: Multiple Myeloma Non-Hodgkin Lymphoma Diffuse Large B Cell Date: 2017-01-11 Interventions: Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells Other |
Recruiting |
Study Name: Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Condition: Chronic Lymphocytic Leukemia Indolent B-cell Lymphomas Date: 2016-12-02 Interventions: Drug: Ibrutinib Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (l |
Not yet recruiting |
Study Name: Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell Lymphoma Condition: B Cell Lymphoma Lymphoma Date: 2016-09-08 Interventions: Drug: Ixazomib The prescribed |
Recruiting |
Study Name: Indolent Non Follicular Lymphomas Prognostic Project Condition: Indolent B-Cell Lymphomas Date: 2016-09-06 Interventions: Other: Any treatment, watch and wait policy included Patients registered in the study despite their plan |
Recruiting |
Study Name: p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies Condition: T-cell Lymphoma Aggressive B-cell Lymphoma Non-Hodgkin's L Date: 2016-07-25 Interventions: Drug: Decitabine 2-4 capsules |
Recruiting |
Study Name: Sofosbuvir+Ledipasvir ±Ribavirin and Sofosbuvir+Ribavirin for Pts With Indolent Bcell Lymphoma Associated With HCV Infection Treatment With Sofosbuvir Plus Ledipasvir ± Ribavirin(G1, 3 and 4) and Sofosbuvir+Ribavirin(G2) for Pts With Hepatitis C Virus Associated Indolent B-cell Lymphomas Condition: Indolent B-cell Lymphoma Hepatitis C Date: 2016-02-25 Interventions: Drug: Sofosbuvir+Ledipasvir |
Recruiting |
Study Name: Ultra Low Dose 4 Gy Orbital Radiation for Definitive Therapy of Indolent B Cell Lymphoma Condition: Lymphoma Date: 2015-07-08 Interventions: Radiation: Radiation Therapy Participants receive radiation to entire involved orbit for a total dose of |
Recruiting |
Study Name: Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma Condition: Lymphoma, Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantl Date: 2014-09-30 Interventions: Drug: Rituximab 375 mg/m2 I.V. |
Recruiting |
Study Name: Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma Condition: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Nodal Marginal Date: 2014-01-28 Interventions: Drug: PI3K inhibitor BKM120 Wi |
Active, not recruiting |
Study Name: A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies Condition: Indolent B-cell Lymphoma Chronic Lymphocytic Leukaemia Date: 2013-03-04 Interventions: Drug: DI-B4 DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose wi |